To read Martin´s biography click on the picture
After his post-doctoral period, he worked as project manager for the establishment of the German Biosafety Program and was responsible for the Eastern European regions of the Southern Caucasus. In addition, he conducted part-time studies in the field of economics and completed a Master of Business Administration in 2017.
In the following two years he worked at HP Medizintechnik GmbH, where he was responsible for the technical development of the CYRIS technology and for its market entry strategy. In this position he created the brand INCYTOИ and organized its foundation as an independent company. Since 2019, Dr. Strehle holds the position of CEO at INCYTOИ GmbH and continues to promote the CYRIS technology in the scientific community.
Advantages of cell-based assays (CBAs) in current research
11th Nov 2020 / 3.00 pm 3o min free life science webinar LANGUAGE: ENGLISH
Cell-based assays are very popular in the field of life sciences. They enable a vast variety of methods and technologies and provide insightful information. In principle, any cell culture laboratory can easily produce biologically and physiologically relevant data. However, there are advantages and disadvantages of the available technologies, and the researcher should be aware of certain limitations. Thus, while focusing on the performance of the assay and seeking an answer to the research question, the appropriate model system should be selected and combined with upstream and downstream technology to create an appropriate data generation process to ensure highly reliable and reproducible data. There is a need not only to create outstanding individual experiments, but also to integrate the studies into seamless workflows and systems.